Get started
Author

Christian Bjerregård Øland

Observed names: C. Bjerregård Øland, Christian B Øland, Christian Bjeeregard Oland, Christian Øland, Christian B Øland
Observed institutions: Statens Serum Institut, Bandim Health Project, University of Southern Denmark, Odense University Hospital, Zealand Pharma (Denmark), Leo Pharma (Denmark)
ORCID: 0000-0001-8929-1761
Observed ORCID: 0000-0001-8929-1761
OpenAlex ID: A5012416645
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial (ECZTRA 7)*
2021 · J. Gutermuth, A.E. Pink, et al. · British Journal of Dermatology · 94
PDF
Maternal Priming: Bacillus Calmette-Guérin (BCG) Vaccine Scarring in Mothers Enhances the Survival of Their Child With a BCG Vaccine Scar
2019 · Mike L T Berendsen, Christian Bjerregård Øland, et al. · Journal of the Pediatric Infectious Diseases Society · 86
PDF
Early Vaccination With Bacille Calmette-Guérin-Denmark or BCG-Japan Versus BCG-Russia to Healthy Newborns in Guinea-Bissau: A Randomized Controlled Trial
2019 · Frederik Schaltz-Buchholzer, Morten Bjerregaard-Andersen, et al. · Clinical Infectious Diseases · 45
PDF
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
2025 · Raj Chovatiya, Simone Ribero, et al. · American Journal of Clinical Dermatology · 24
Maternal BCG primes for enhanced health benefits in the newborn
2021 · Frederik Schaltz-Buchholzer, Christian Bjerregård Øland, et al. · Journal of Infection · 12
PDF
Reduced Mortality After Oral Polio Vaccination and Increased Mortality After Diphtheria-tetanus-pertussis Vaccination in Children in a Low-income Setting
2020 · Christian Bjerregård Øland, Søren Wengel Mogensen, et al. · Clinical Therapeutics · 12
PDF
Understanding the child mortality decline in Guinea-Bissau: the role of population-level nutritional status measured by mid-upper arm circumference
2022 · Andreas Rieckmann, Ane Bærent Fisker, et al. · International Journal of Epidemiology · 11
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials
2025 · Kristian Reich, Richard G Langley, et al. · British Journal of Dermatology · 9
PDF
Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome
2024 · Christian Bjerregård Øland, Lise Skov Ranch, et al. · PLoS ONE · 6
551 - Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control
2024 · Andrew Blauvelt, Richard G Langley, et al. · British Journal of Dermatology · 6
Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis
2025 · Melinda Gooderham, Mahreen Ameen, et al. · Journal of the European Academy of Dermatology and Venereology · 5
PDF
Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years
2025 · Andrew Blauvelt, Vivian Laquer, et al. · SKIN The Journal of Cutaneous Medicine · 3
PDF
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials
2024 · Kristian Reich, Richard G Langley, et al. · British Journal of Dermatology · 3
Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials
2024 · Kristian Reich, Richard G. Langley, et al. · SKIN The Journal of Cutaneous Medicine · 3
PDF
650 - Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
2024 · Andrew Blauvelt, H Chih-ho Hong, et al. · British Journal of Dermatology · 2
53133 Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
2024 · Andrew Blauvelt, Chi-ho Hong, et al. · Journal of the American Academy of Dermatology · 1
PDF
Stability of Long-Term Therapeutic Responses to Tralokinumab in Adults with Moderate-to-Severe Atopic Dermatitis
2024 · Andrew Blauvelt, Chih-ho Hong, et al. · SKIN The Journal of Cutaneous Medicine · 1
555 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials
2024 · Kristian Reich, Richard G Langley, et al. · British Journal of Dermatology · 1
Erratum to ‘Maternal BCG primes for enhanced health benefits in the newborn’ [Journal of Infection Volume 84, Issue 3 (2022) 321-328]
2022 · Frederik Schaltz-Buchholzer, Christian Bjerregård Øland, et al. · Journal of Infection · 1
117: Long-term efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis
2025 · Andreas Wollenberg, Amy Paller, et al. · Journal of Investigative Dermatology
PDF
651 - Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
2024 · Raj Chovatiya, Andreas Wollenberg, et al. · British Journal of Dermatology
Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control
2024 · Andrew Blauvelt, Richard G. Langley, et al. · SKIN The Journal of Cutaneous Medicine
PDF
552 - Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
2024 · Raj Chovatiya, Andreas Wollenberg, et al. · British Journal of Dermatology
Improvement of the Head and Neck Regions with Continuous Tralokinumab treatment for Up to 4 years in Adults with Moderate-to-Severe Atopic Dermatitis
2024 · Raj Chovatiya, Andreas Wollenberg, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial
2021 · Jan Gutermuth, Andrew Pink, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Works count: 26
Citation count: 325
H-index: 8
I10-index: 7
Year
Topic
Type